These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 16392821)
1. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. Disingrini T; Muth M; Dallanoce C; Barocelli E; Bertoni S; Kellershohn K; Mohr K; De Amici M; Holzgrabe U J Med Chem; 2006 Jan; 49(1):366-72. PubMed ID: 16392821 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vitro pharmacology of novel heterocyclic muscarinic ligands. De Amici M; Conti P; Fasoli E; Barocelli E; Ballabeni V; Bertoni S; Impicciatore M; Roth BL; Ernsberger P; De Micheli C Farmaco; 2003 Sep; 58(9):739-48. PubMed ID: 13679167 [TBL] [Abstract][Full Text] [Related]
3. Novel oxotremorine-related heterocyclic derivatives: Synthesis and in vitro pharmacology at the muscarinic receptor subtypes. Dallanoce C; De Amici M; Barocelli E; Bertoni S; Roth BL; Ernsberger P; De Micheli C Bioorg Med Chem; 2007 Dec; 15(24):7626-37. PubMed ID: 17889543 [TBL] [Abstract][Full Text] [Related]
4. Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents. Muth M; Sennwitz M; Mohr K; Holzgrabe U J Med Chem; 2005 Mar; 48(6):2212-7. PubMed ID: 15771463 [TBL] [Abstract][Full Text] [Related]
5. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174 [TBL] [Abstract][Full Text] [Related]
6. Development of a new type of allosteric modulator of muscarinic receptors: hybrids of the antagonist AF-DX 384 and the hexamethonio derivative W84. Mohr M; Heller E; Ataie A; Mohr K; Holzgrabe U J Med Chem; 2004 Jun; 47(12):3324-7. PubMed ID: 15163212 [TBL] [Abstract][Full Text] [Related]
7. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC Mol Pharmacol; 2014 Jul; 86(1):106-15. PubMed ID: 24807965 [TBL] [Abstract][Full Text] [Related]
9. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612 [TBL] [Abstract][Full Text] [Related]
10. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor. Redka DS; Pisterzi LF; Wells JW Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124 [TBL] [Abstract][Full Text] [Related]
12. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators. May LT; Lin Y; Sexton PM; Christopoulos A J Pharmacol Exp Ther; 2005 Jan; 312(1):382-90. PubMed ID: 15333678 [TBL] [Abstract][Full Text] [Related]
13. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. Lanzafame AA; Sexton PM; Christopoulos A Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of 1-methyl-5-(pyrazol-3- and -5-yl- and 1, 2, 4-triazol-3- and 5-yl)-1, 2, 3, 6-tetrahydropyridine derivatives and their evaluation as muscarinic receptor ligands. Del Giudice MR; Mustazza C; Borioni A; Gatta F; Tayebati K; Amenta F; Tucci P; Pieretti S Arch Pharm (Weinheim); 2003 Jun; 336(3):143-54. PubMed ID: 12822179 [TBL] [Abstract][Full Text] [Related]
15. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Jakubík J; Bacáková L; El-Fakahany EE; Tucek S Mol Pharmacol; 1997 Jul; 52(1):172-9. PubMed ID: 9224827 [TBL] [Abstract][Full Text] [Related]
16. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. Avlani V; May LT; Sexton PM; Christopoulos A J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931 [TBL] [Abstract][Full Text] [Related]
17. Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives. Dei S; Angeli P; Bellucci C; Buccioni M; Gualtieri F; Marucci G; Manetti D; Matucci R; Romanelli MN; Scapecchi S; Teodori E Biochem Pharmacol; 2005 Jun; 69(11):1637-45. PubMed ID: 15896343 [TBL] [Abstract][Full Text] [Related]
18. Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Varoli L; Andreani A; Burnelli S; Granaiola M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Bedini A; Fazio N; Spampinato S Bioorg Med Chem Lett; 2008 May; 18(9):2972-6. PubMed ID: 18395442 [TBL] [Abstract][Full Text] [Related]
19. Contribution of lateral substituents in symmetrical and non-symmetrical heptane-bisammonio compounds to the allosteric stabilization of N-methylscopolamine binding to muscarinic M2 receptors. Staudt M; Tränkle C; Mohr K; Holzgrabe U Arch Pharm (Weinheim); 2003 Aug; 336(8):385-9. PubMed ID: 14502759 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M. Dallanoce C; Conti P; De Amici M; De Micheli C; Barocelli E; Chiavarini M; Ballabeni V; Bertoni S; Impicciatore M Bioorg Med Chem; 1999 Aug; 7(8):1539-47. PubMed ID: 10482446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]